Co-delivered PD-L1 rescues the protective efficacy mediated by an AAV-expressed HIV-1 bNAb
Kuipa, M.; Koroma, A. A.; Leguizamo, I.; Dhole, P.; Barot, Y.; Lee, M. Y.- H.; Tharp, G. K.; Liang, S.; Chouinard, M.; Ehnert, S.; Weissman, S.; Whitehead, C.; Stammen, R. L.; Wood, J. S.; Curran, E. H.; Machiah, D.; Dessasau, E. D.; Nishimura, Y.; Xie, J.; Gao, G.; Verma, S.; Kulpa, D. A.; Moore, I. N.; Bosinger, S. E.; Gardner, M. R.
Show abstract
Adeno-associated virus (AAV)-delivered anti-HIV-1 broadly neutralizing antibodies (bNAbs) could prevent and treat HIV-1 infection but are limited by host immune responses, specifically anti-drug antibodies (ADA). We tested whether PD-L1-mediated immune shielding could improve the consistency of AAV-delivered bNAb expression from muscle tissue in rhesus macaques. AAV9.PD-L1 co-delivery with AAV9.3BNC117 reduced the occurrence of ADA and T cell responses and improved the durability of 3BNC117 expression for one year post administration. Importantly, 5 of 6 macaques that received co-delivered AAV9.PD-L1 vectors were protected against ten repeated SHIVAD8-EO challenges. Histopathological and spatial transcriptomic profiling showed that AAV9.PD-L1 co-delivery prevented severe local inflammation, muscle injury, and tertiary lymphoid structure formation at the administration site. Thus, immune shielding could serve as a strategy to prolong transgene expression from muscle-directed AAV-delivered biologics.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.